The European Medicines Agency, EMA, has given authorisation for the Spikevax vaccine, formerly known as Moderna, to be administered to those in the 12 to 17 age group.
The vaccination will be given the same as for adults, being two doses with a four-week gap.
This decision was taken following a survey among 3,732 children in this age group.
The study found it is just as efficient in this band as it is in those over the age of 18.
Even the main side-effects observed in children are the same as those seen in adults.
These included swelling in the arm, fatigue, headaches, and fever, but all these were moderate in all instances.